Coherus Oncology (CHRS) Interest Coverage Ratio Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) Interest Coverage Ratio Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 33.30% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 78.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 81.16% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -35.50% |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -58.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.82% |
| Mar 31, 2026 | -33.34% |
| Dec 31, 2025 | -49.75% |
| Sep 30, 2025 | -15.96% |
| Jun 30, 2025 | -33.69% |
| Mar 31, 2025 | 16.87% |
| Dec 31, 2024 | -1.18% |
| Sep 30, 2024 | -44.75% |
| Jun 30, 2024 | -32.38% |
| Mar 31, 2024 | 9.81% |
| Dec 31, 2023 | -104.39% |
| Sep 30, 2023 | -36.13% |
| Jun 30, 2023 | -31.76% |
| Mar 31, 2023 | -31.28% |
| Dec 31, 2022 | -35.03% |
| Sep 30, 2022 | -42.93% |
| Jun 30, 2022 | -45.47% |
| Mar 31, 2022 | -31.84% |
| Dec 31, 2021 | -36.53% |
| Sep 30, 2021 | 38.50% |